Name: ERGOMED PLC (2EM) Stock
Brand: ERGOMED PLC
Rating: 4.5 (3 reviews)

Question 1

Can you describe the business of ERGOMED PLC?

Accepted Answer

Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey and currently employs 1,255 full-time employees. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm serves over 100 countries. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.

Question 2

What is the stock price of ERGOMED PLC today?

Accepted Answer

The current stock price of 2EM.DE is 11 EUR. The price decreased by -3.68% in the last trading session.

Question 3

Does 2EM stock pay dividends?

Accepted Answer

2EM.DE does not pay a dividend.

Question 4

What is the ChartMill rating of ERGOMED PLC stock?

Accepted Answer

2EM.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.

Question 5

What do analysts say about ERGOMED PLC (2EM.DE) stock?

Accepted Answer

12 analysts have analysed 2EM.DE and the average price target is 16.93 EUR. This implies a price increase of 53.9% is expected in the next year compared to the current price of 11.

Question 6

Can you provide the growth outlook for ERGOMED PLC?

Accepted Answer

The Revenue of ERGOMED PLC (2EM.DE) is expected  to grow  by 12.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.

ERGOMED PLC (2EM.DE) Stock Price, Forecast & Analysis

2EM.DE Latest News, Press Relases and Analysis